Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

McKesson to buy pharma tech firm Rx Savings for up to $875 million

Published 09/19/2022, 09:18 AM
Updated 09/19/2022, 10:30 AM
© Reuters. FILE PHOTO: Boxes containing the Moderna COVID-19 vaccine are prepared to be shipped at the McKesson distribution center in Olive Branch, Mississippi, U.S. December 20, 2020. Paul Sancya/Pool via REUTERS
MCK
-

(Reuters) -Drug distributor McKesson Corporation (NYSE:MCK) said on Monday it would acquire private pharma technology firm Rx Savings Solutions for up to $875 million.

The company helps health insurers and employers seek lower cost prescription medicines, and also provides ongoing medication reminders to help improve adherence to prescriptions.

© Reuters. FILE PHOTO: Boxes containing the Moderna COVID-19 vaccine are prepared to be shipped at the McKesson distribution center in Olive Branch, Mississippi, U.S. December 20, 2020. Paul Sancya/Pool via REUTERS

"Rx Savings Solutions’ offerings for employers and patients will strengthen McKesson’s ability to help solve the most common medication challenges related to access, affordability and adherence," McKesson Chief Executive Officer Brian Tyler said.

The transaction, which includes a $600 million upfront payment and up to $275 million contingent on Rx Savings' financial performance through 2025, is expected to close in the second half of fiscal year 2023.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.